Current trends in the management of ocular symptoms in Adamantiades- Behçet's disease

Clinical Ophthalmology

Volumn 3, Issue 1, 2009, Pages 567-579

  Zakka, Fouad R ^a   Chang, Peter Y ^a   Giuliari, Gian P ^a   Foster, C Stephen ^a,b  

^a MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adamantiades Beh et's disease; Beh et's disease; Immunomodulatory therapy; Immunosuppressive therapy; Ocular inflammation; Uveitis

Indexed keywords

ALPHA INTERFERON; AMMONIUM CHLORIDE; AZATHIOPRINE; BETA INTERFERON; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; ETANERCEPT; FLUOROMETHOLONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA B27 ANTIGEN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PENTOXIFYLLINE; PREDNISOLONE; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

AGRANULOCYTOSIS; ALOPECIA; ANOREXIA; APLASTIC ANEMIA; AZOOSPERMIA; BEHCET DISEASE; BLOOD VESSEL INJURY; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; CATARACT; CLINICAL FEATURE; CUSHINGOID SYNDROME; DIARRHEA; DRUG BIOAVAILABILITY; DRUG MEGADOSE; DRUG METABOLISM; EARLY DIAGNOSIS; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERTROPHY; GLAUCOMA; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFERTILITY; LASER COAGULATION; LEUKAPHERESIS; LIMB PAIN; LIVER TOXICITY; LOW DRUG DOSE; MORNING DOSAGE; MUSCLE WEAKNESS; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PARALYSIS; PARESTHESIA; PATHOPHYSIOLOGY; PEPTIC ULCER; PERIPHERAL NEUROPATHY; PHOCOMELIA; PHOTOSENSITIVITY; PSYCHOSIS; RETINA NEOVASCULARIZATION; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN NODULE; SYNDROME DELINEATION; TERATOGENESIS; TRABECULECTOMY; URTICARIA; VASCULITIS; VITRECTOMY; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 77953378844     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: None     Document Type: Review

References (135)

1. Hippocrates. In: Dilsen N, Kaktos, Editor. Third book on epidemiology. Case 7. 1993; p. 209.
2. Adamantiades B. A case of recurrent hypopyon iritis. Medical Society of Athens. 1930;586-593.
3. Behçet H. Uber rezidivierende aphthose, durch ein Virus verursachte Geschwure am Mud, am Auge und an den Genitalien. Derm Wochenschr. 1937;36:1152-1157.
4. Ohno S. Behçet's disease in the World. In: Lehner T, Barnes CG, editors. Recent Advances in Behçet's Disease. London: Royal Society of Medicine Service; 1986.
5. Chajek T, Fainaru M. Behçet's disease: Report of 41 cases and a review of the literature. Medicine. 1975;54(3):179-196.
6. O'Duffy JD: Behçet's disease. In: Kelly WN, Harris ED, Ruddy S, Sledge CB, editors. Textbook of Rheumatology. Philadelphia: WB Saunders; 1985;1174-1178.
7. Mamo JG, Baghdassarian A. Behçet's disease: A report of 28 cases. Arch Ophthalmol. 1964;71:4-14.
8. Shimizu T. Clinical and immunological studies on Behçet's syndrome. Folia Ophthalmol Jpn. 1971;22(10):801-810.
9. Mizuki N, Ohno S, Ando H, et al. A strong association between HLA-B*5101 and Behçet's disease in Greek patients. Tissue Antigen. 1997:50(1):57-60.
10. Ohno S, Ohguchi M, Hirose S, et al. Close association of HLA-Bw51 with Behçet's disease. Arch Ophthalmol. 1982;100(9):1455-1458.
11. Mishima S, Masuda K, Izawa Y, et al. Behçet's disease in Japan: Ophthalmologic aspects. Trans Am Ophthalmol Soc. 1979;76:225-279.
12. Lehner T, Barnes CG. Criteria for diagnosis and classification of Behçet's syndrome. In: Lehner T, Barnes CG, editors. Behçet's Syndrome: Clinical and Immunological Features. Proceedings of a Conference Sponsored by Royal Society of Medicine, February 1979. London: Academic Press. 1979;1-9.
13. Numaga J, Matsuki M, Mochizuki M, et al. An HLA-D region restriction fragment associated with refractory Behçet's disease. Am J Ophthalmol. 1988;105(5):528-533.
14. Shikano S. Ocular pathology of Behçet's syndrome. In: Monacelli M, Nazzaro P, editors. International Symposium on Behçet's Disease. New York: Karger, Basel. 1966;111-136.
15. Lakhanpal SH, Tani K, Lie JT, et al. Pathologic features of Behçet's syndrome: A review of Japanese autopsy registry data. Hum Pathol. 1985;16(8):790-795.
16. Behçet's Disease Research Committee of Japan. Behçet's disease: Guide to diagnosis of Behçet's disease. Jpn J Ophthalmol. 1974;18:291-294.
17. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet. 1990;335(8697):1078-1080.
18. Pande I, Uppal S, Kailash S, et al. Behçet's disease in India: A clinical, immunological, immunogenetic and outcome study. Br J Rheumatol. 1995;34(9):825-830.
19. Benamour S, Zeroual B, Bennis R, et al. Maladie de Behçet. 316 cas. La Presse Med. 1990;19(32):1485-1489.
20. Dilsen N, Konice K, Aral O, et al. Risk factors for vital organ involvement in Behçet's disease. In: Godeau P, Wechsler B, editors. Behçet's Disease. New York: Elsevier Science. 1993;165-169.
21. Gharibdoost F, Davatchi F, Shahram F, et al. Clinical manifestations of Behçet's disease in Iran: Analysis of 2176 casese. In: Godeau P, Wechsler B, editors. Behçet's Disease. New York: Elsevier Science, 1993;153-158.
22. Imai Y. Studies on prognosis and symptoms of Behçet's disease in long-term observation. Jpn J Clin Ophthalmol. 1971;25:665-694.
23. Benezra D, Cohen E. Treatment and visual prognosis in Behçet's disease. Br J Opthalmol. 1986 Aug;70(8):589-592.
24. Kaklamai VG, Kaklamanis PG. Treatment of Behçet's disease: an update. Semi Arthritis Rheum. 2001;30:299-312.
25. Toker E, Kazokoglu H, Acar N. High dose intravenous steroid therapy for severe posterior segment uveitis in Behçet's disease. Br J Ophthalmol. 2002 May;86(5):521-523.
26. Evereklioglu C. Managing the symptoms of Behçet's disease. Expert Opin Pharmacother. 2004;5(2):317-328.
27. Tugal-Tutkun I, Önal S, Altan Yaycioglu R, et al. Uveitis in Behçet's disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373-380.
28. Standarization of Uveitis Nomenclature (SUN) Working Group. Standarization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol. 2005 Sep;140(3):509-516.
29. Yoshikawa K, Ichiishi A, Kotabe S, et al. Posterior sub-Tenon's space injection of repository corticosteroids in uveitis patients with cystoid macular edema. Nippon Ganka Gakkai Zasshi. 1993;97(9):1070-1074.
30. Rothova A. Medical treatment of cystoid macular edema. Ocul Immunol Inflamm. 2002;10(4):239-246.
31. Fine H, Baffi J, Reed GF, et al. Aqueous humor and plasma vascular endothelial growth factor in uveitis associated cystoid macular edema. Am J Ophthalmol. 2001;132(5):794-796.
32. Cordero-Coma M, Sobrin L, Onal S, et al. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology. 2007;114(8): 1574-1579.
33. Okada AA. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm. 2005;13(5):335-351.
34. Kötter I, Dürk H, Saal J, Fierlbeck G, Pleyer U, Ziehut M. Therapy of Behçet's disease. Ger J Ophthalmol. 1996;5(2):92-97.
35. Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behçet's syndrome: effects on long-term prognosis. Arthritis Rheum. 1997;40(4):769-774.
36. Greenwood AJ, Stanford MR, Graham EM. The role of azathioprine in the management of retinal vasculitis. Eye. 1998;12(5):783-788.
37. Sakane T, Takeno M, Suzuki N, Inaba G, et al. Behçet's disease. N Engl J Med. 1999;341(17):1284-1291.
38. Foster CS, Baeyer JC, Raizman MB. Therapeutic response to systemic immunosuppressive chemotherapy agents in patients with Behçet's syndrome affecting the eyes. In: O'Duffy KE, editor. Behçet's Disease: Basic and Clinical Aspects. New York: Marcel Dekker. 1991;581-588.
39. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492-513.
40. Davatchi F, Shahram F, Chams H, et al. High dose methotrexate for ocular lesions of Behçet's disease. Preliminary short-term results. Adv Exp Med Biol. 2003;528:579-584.
41. Ghate JV, Jorizzo JL. Behçet's disease and complex aphthosis. J Am Acad Dermatol. 1999;40(1):1-18; quiz 19-20.
42. Hirohata S, Suda H, Hashimoto T. Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behçet's disease. J Neurol Sci. 1998;159(2):181-185.
43. Weinblatt ME. Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol Suppl. 1985;12 Suppl 12:35-39.
44. Kremer JM, Alarcón GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 1994;37(3): 316-328.
45. Walker AM, Funch D, Dreyer NA, et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum. 1993;36(3):329-335.
46. Kempen JH, Gangaputra S, Daniel E, et al. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol. 2008;146(6):802-812 e1.
47. Yu T, Yu TF. Milestones in the treatment of gout. Am J Med. 1974; 56(5):676-685.
48. Ehrenfeld M, Levy M, Bar Eli M, Gallily R, Eliakim M. Effect of colchicine on polymorphonuclear leucocyte chemotaxis in human volunteers. Br J Clin Pharmacol. 1980;10(3):297-300.
49. Malawista SE. The action of colchicine in acute gouty arthritis. Arthritis Rheum, 1975;18(6 Suppl):835-846.
50. Pesanti EL, SG Axline. Colchicine effects on lysosomal enzyme induction and intracellular degradation in the cultivated macrophage. J Exp Med. 1975;141(5):1030-1046.
51. Frayha RA. Arthropathy of Behçet's disease with marked synovial pleocytosis responsive to colchicine. Arthritis Rheum. 1982;25(2):235-236.
52. Ando K, Fujino Y, Hijikata K, Izawa Y, Masuda K. Epidemiological features and visual prognosis of Behçet's disease. Jpn J Ophthalmol. 1999;43(4):312-317.
53. Matsumura N, Mizushima Y. Leucocyte movement and colchicine treatment in Behçet's disease. Lancet. 1975;2(7939):813.
54. Mizushima Y, Matsumura N, Mori M, et al. Colchicine in Behçet's disease. Lancet. 1977;2(8046):1037.
55. Raynor A, Askari AD. Behçet's disease and treatment with colchicine. J Am Acad Dermatol. 1980;2(5):396-400.
56. Fontes V, Machet L, Huttenberger B, Lorette G, Vaillant L. [Recurrent aphthous stomatitis: treatment with colchicine. An open trial of 54 cases]. Ann Dermatol Venereol. 2002;129(12):1365-1369.
57. Mizushima Y. Behçet's disease. Curr Opin Rheumatol. 1991; 3(1):32-35.
58. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet. 1989; 1(8647):1093-1096.
59. Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol. 2005;50(4):297-350.
60. Gilman AG GL, Rall TW, Murad F. The Pharmacological Basis of Therapeutics. New York: Macmillan Publishing Company. 1985;709.
61. Newell DR, Calvert AH, Harrap KR, McElwain TJ. Studies on the pharmacokinetics of chlorambucil and prednimustine in man. Br J Clin Pharmacol. 1983;15(2):253-258.
62. Mamo JG, Azzam SA. Treatment of Behçet's disease with chlorambucil. Arch Ophthalmol. 1970;84(4):446-450.
63. Tessler HH, Jennings T. High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behçet's disease. Br J Ophthalmol. 1990;74(6):353-357.
64. Mudun BA, Ergen A, Ipcioglu SU, Burumcek EY, Durlu Y, Arslan MO. Short-term chlorambucil for refractory uveitis in Behçet's disease. Ocul Immunol Inflamm. 2001;9(4):219-229.
65. Goldstein DA, Fontanilla FA, Kaul S, Sahin O, Tessler HH. Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology. 2002;109(2):370-377.
66. Miserocchi E, Baltatzis S, Ekong A, Roque M, Foster CS. Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience. Ophthalmology. 2002;109(1):137-142.
67. Grupe WE. Chlorambucil in steroid-dependent nephrotic syndrome. J Pediatr. 1973;82(4):598-606.
68. Guesry P, Lenoir G, Broyer M. Gonadal effects of chlorambucil given to prepubertal and pubertal boys for nephrotic syndrome. J Pediatr. 1978;92(2):299-303.
69. Richter P, Calamera JC, Morgenfeld MC, Kierszenbaum AL, Lavieri JC, Mancini RE. Effect of chlorambucil on spermatogenesis in the human with malignant lymphoma. Cancer. 1970;25(5):1026-1030.
70. Callis L, Nieto J, Vila A, Rende J. Chlorambucil treatment in minimal lesion nephrotic syndrome: a reappraisal of its gonadal toxicity. J Pediatr. 1980;97(4):653-656.
71. Moore MJ. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 1991;20(3):194-208.
72. Grochow LB, Colvin M. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 1979;4(5):380-394.
73. Shek LP, Lim DL. Thalidomide in Behçet's disease. Biomed Pharmacother. 2002;56(1):31-35.
74. Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med. 2000;108(6):487-495.
75. Rabinowitz R, Katz G, Rosner M, Pri-Chen S, Spierer A. The effect of thalidomide on neovascularization in a mouse model of retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2008;246(6): 843-848.
76. Lambert K, Ward J. The use of thalidomide in the management of bleeding from a gastric cancer. Palliat Med. 2009;23(5):473-475.
77. Alberto SF, Felix J, de Deus J. Thalidomide for the treatment of severe intestinal bleeding. Endoscopy. 2008;40(9):788; author reply 789.
78. Bauditz J, Lochs H. Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding. World J Gastroenterol. 2007;13(45):5979-5984.
79. Dabak V, Kuriakose P, Kamboj G, Shurafa M. A pilot study of thalidomide in recurrent GI bleeding due to angiodysplasias. Dig Dis Sci. 2008;53(6):1632-1635.
80. Gardner-Medwin JM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis. 1994;53(12):828-832.
81. Eisenbud L, Horowitz I, Kay B. Recurrent aphthous stomatitis of the Behçet's type: successful treatment with thalidomide. Oral Surg Oral Med Oral Pathol. 1987;64(3):289-292.
82. Treves R, Arnaud M, Jacob P, et al. [Speculative ameloriation of arthritis in Behçet disease with thalidomide. A case report]. Rev Rhum Mal Osteoartic. 1984;51(10):585.
83. Hamza MH. Treatment of Behçet's disease with thalidomide. Clin Rheumatol. 1986;5(3):365-371.
84. Mellin GW, Katzenstein M. The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies. N Engl J Med. 1962;267:1238-1244.
85. Ochonisky S, Verroust J, Bastuji-Garin S, Gherardi R, Revuz J. Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch Dermatol. 1994;130(1):66-69.
86. De Tran QH, Guay E, Chartier S, Tousignant J. Tacrolimus in dermatology. J Cutan Med Surg. 2001;5(4):329-335.
87. Dick AD. Experimental approaches to specific immunotherapies in autoimmune disease: future treatment of endogenous posterior uveitis? Br J Ophthalmol. 1995;79(1):81-88.
88. Mochizuki M. Immunotherapy for Behçet's disease. Int Rev Immunol. 1997;14(1):49-66.
89. Figueroa MS, Ciancas E, Orte L. Long-term follow-up of tacrolimus treatment in immune posterior uveitis. Eur J Ophthalmol. 2007;17(1):69-74.
90. Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology. 1999;106(4):723-728.
91. Hogan AC, McAvoy CE, Dick AD, Lee RW. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology. 2007;114(5):1000-1006.
92. Belardelli F, Gresser I. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol Today. 1996;17(8):369-372.
93. Feron EJ, Rothova A, van Hagen PM, Baarsma GS, Suttorp-Schulten MS. Interferon-alpha 2b for refractory ocular Behçet's disease. Lancet. 1994;343(8910):1428.
94. Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol. 2006;244(12):1692-1695.
95. Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol. 2008;146(6): 837-844 e1.
96. Freysdottir J, Lau S, Fortune F. Gammadelta T cells in Behçet's disease (BD) and recurrent aphthous stomatitis (RAS). Clin Exp Immunol. 1999;118(3):451-457.
97. Turan B, Gallati H, Erdi H, Gurler A, Michel BA, Villiger PM. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechcet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol. 1997;24(1):128-132.
98. Haznedaroglu E, Karaaslan Y, Buyukasik Y, et al. Selectin adhesion molecules in Behçet's disease. Ann Rheum Dis. 2000;59(1):61-63.
99. Sf ikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behçet's disease - review and basis for recommendations. Rheumatology (Oxford). 2007;46(5): 736-741.
100. Goossens PH, Verburg RJ, Breedveld FC. Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy. Ann Rheum Dis. 2001;60(6):637.
101. Sfikakis PP. Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis. 2002;61 Suppl 2:ii51-ii53.
102. Sf ikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet. 2001;358(9278):295-296.
103. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med. 2004;140(5):404-406.
104. Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology (Oxford). 2007;46(7): 1161-1164.
105. Tognon S, Graziani G, Marcolongo R. Anti-TNF-alpha therapy in seven patients with Behçet's uveitis: advantages and controversial aspects. Ann N Y Acad Sci. 2007;1110:474-484.
106. Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Ann Rev Med. 2000;51:207-229.
107. Thomas-Golbanov C, Sridharan S. Novel therapies in vasculitis. Exp Opin Invest Drug. 2001;10:1279-1289.
108. Melikoglu M, Özyazgan Y, Fresko I, et al. The response of treatment resistant uveitis in Behçet's syndrome (BS) to a TNF-α blocker, etanercept: an open study. Arthritis Rheum. 2002;46:181.
109. Evans CA, Jellis J, Hughes SP, et al. Tumor necrosis factor-α, interleukin-6, and interleukin-8 secretion and the acute-phase response in patients with bacterial and tuverculous osteomyelitis. J Infect Dis. 1998;177:1582-1587.
110. Yücel AE, Kart-Köseoglu H, Akova YA, et al. Failure of infliximab treatment and occurrence of erythema nodosum during therpy in two patients with Behçet's disease. Rheumatology. 2004;43:394-396.
111. Tognon S, Graziani G, Marcolongo R. Anti-TNF-alpha therapy in seven patients with Behçet's uveitis: advantages and controversial aspects. Ann N Y Acad Sci. 2007;1110:474-484.
112. Yasui K, Ohta K, Kobayashi M, Aizawa T, Komiyama A. Successful treatment of Behçet disease with pentoxifylline. Ann Intern Med. 1996;124(10):891-893.
113. Accardo-Palumbo A, Ferrante A, Ciccia F, et al. Pentoxifylline inhibits Vgamma9/Vdelta2 T lymphocyte activation of patients with active Behçets disease in vitro. Int J Immunopathol Pharmacol. 2007;20(3):601-606.
114. Namba K, Sonoda KH, Kitamei H, et al. Granulocytapheresis in patients with refractory ocular Behçet's disease. J Clin Apher. 2006;21(2):121-128.
115. Rojas B, Zafirakis P, Foster CS. Cataract surgery in patients with uveitis. Curr Opin Ophthalmol. 1997;8:6-12.
116. Sullu Y, Oge I, Erkan D. The results of cataract extraction and intraocular lens implantation in patients with Behçet's disease. Acta Ophthalmol Scand. 2000;78(6):680-683.
117. Berker N, Soykan E, Elgin U, Ozkan SS. Phacoemulsification cataract extraction and intraocular lens implantation in patients with Behçet's disease. Ophthalmic Surg Lasers Imaging. 2004;35(3):215-218.
118. Kadayifcilar S, Gedik S, Eldem B, Irkec M. Cataract surgery in patients with Behçet's disease. J Cataract Refract Surg. 2002;28(2):316-320.
119. Da Mata A, Burk SE, Netland PA, Baltatzis S, Christen W, Foster CS. Management of uveitic glaucoma with Ahmed glaucoma valve implantation. Ophthalmology. 1999;106(11):2168-2172.
120. Hill RA, Nguyen QH, Baerveldt G, et al. Trabeculectomy and Molteno implantation for glaucomas associated with uveitis. Ophthalmology. 1993;100(6):903-908.
121. Jampel HD, Jabs DA, Quigley HA. Trabeculectomy with 5- fluorouracil for adult inflammatory glaucoma. Am J Ophthalmol. 1990;109(2): 168-173.
122. Patitsas CJ, Rockwood EJ, Meisler DM, Lowder CY. Glaucoma filtering surgery with postoperative 5-fluorouracil in patients with intraocular inflammatory disease. Ophthalmology. 1992;99(4):594-599.
123. Prata JA Jr, Neves RA, Minckler DS, Mermoud A, Heuer DK. Trabeculectomy with mitomycin C in glaucoma associated with uveitis. Ophthalmic Surg. 1994;25(9):616-660.
124. Towler HM, McCluskey P, Shaer P, Lightman S. Long-term follow-up of trabeculectomy with intraoperative 5-fluorouracil for uveitis-related glaucoma. Ophthalmology. 2000;107(10):1822-1828.
125. Ceballos EM, Beck AD, Lynn MJ. Trabeculectomy with antiproliferative agents in uveitic glaucoma. J Glaucoma. 2002;11(3):189-196.
126. Yalvac IS, Sungur G, Turhan E, Eksioglu U, Duman S. Trabeculectomy with mitomycin-C in uveitic glaucoma associated with Behçet's disease. J Glaucoma. 2004;13(6):450-453.
127. Ozdemir O, Erkam N, Bakkaloglu A. Results of pars plana vitrectomy in Behçet's disease. Ann Ophthalmol. 1988;20(1):35-38.
128. Soylu M, Demircan N, Pelit A. Pars plana vitrectomy in ocular Behçet's disease. Int Ophthalmol. 2001;24(4):219-223.
129. Ozerturk Y, Bardak Y, Durmus M. Vitreoretinal surgery in Behçet's disease with severe ocular complications. Acta Ophthalmol Scand. 2001;79(2):192-196.
130. Sullu Y, Alotaiby H, Beden U, Erkan D. Pars plana vitrectomy for ocular complications of Behçet's disease. Ophthalmic Surg Lasers Imaging. 2005;36(4):292-297.
131. Krause L, Altenburg A, Bechrakis NE, Willerding G, Zouboulis CC, Foerster MH. Intraocular surgery under systemic interferon-alpha therapy in ocular Adamantiades-Behçet's disease. Graefes Arch Clin Exp Ophthalmol. 2007;245(11):1617-1621.
132. Atmaca LS. Experience with photocoagulation in Behçet's disease. Ophthalmic Surg. 1990;21:571-576.
133. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Kir N, Urgancioglu M. Neovascularization of the optic disc in Behçet's disease. Jpn J Ophthalmol. 2006;50(3):256-265.
134. Newman NM, Hoyt WF, Spencer WH. Macula-sparing monocular blackouts: Clinical and pathologic investigation of intermittent choroidal vascular insufficiency in a case of periarteritis nodosa. Arch Ophthalmol. 1974;91(5):367-370.
135. Gold DH. Ocular manifestations of connective tissue (collagen) diseases. In: Tasman W, Jaeger AE, editors. Duane's Clinical Ophthalmology. Philadelphia: J.B. Lippincott. 1989; 5:17-19.